We developed our ADC technology to enable the creation of better therapies for people with cancer. Today ImmunoGen is a recognized leader in the field.

The concept of an ADC is simple: employ an antibody that binds to a target (its antigen) found on tumor cells to deliver a cancer-killing agent specifically to these cells.

The achievement of an effective ADC is far more challenging. One reason is that the best ADC design – type of cancer-killing agent and method of attachment – varies among different targets and cancer types.

ImmunoGen has built a rich portfolio of ADC technologies. These include alternative types of cancer-killing agents – our tubulin-acting maytansinoids and our DNA-acting IGNs – and of attachment chemistries.

Our technology is used in Roche's Kadcyla® (ado-trastuzumab emtansine) – the only ADC approved to treat a type of solid tumor – and in two other ADCs now in advanced testing for different types of solid tumors.

Kadcyla® is a registered trademarks of Genentech, a member of the Roche Group.

Last updated: February 10, 2016

You are now leaving this website. If you would like to continue, click Continue.